Last updated 2026-08-20
- Raised $110M Series B led by Temasek, Jul 2022
- Raised Seed round, 2021
- Receives FDA IND Clearance for RXIM002, Aug 2026
Total raised
$110.0M
Last: B Round 2022-07
Stage
Series B
Founded
2021
Headcount
—
HQ
Shanghai, China
Sector
Drug Discovery
Website ↗Registrar ID: 516590643 (RiboX Therapeutics Ltd.)
About
RiboX Therapeutics is a global, clinical-stage biotechnology company dedicated to discovering and developing fully engineered circular RNA (circRNA) therapeutics. The company aims to overcome the limitations of mRNA therapeutics and realize the full potential of RNA medicines. Its pipeline spans various therapeutic areas, including radiation-induced xerostomia, monogenic rare diseases, autoimmune diseases, and metabolic diseases. RiboX has operations in China, the US, and Israel.
Funding history · 2 rounds · $110.0M total
2 events/rounds · $110.0M Total Funding: $110.0M in Private Equity
Jul 2022
★ Temasek★ Eisai Innovation★ Lilly Asia Ventures★ Qiming Venture Partners★ Boehringer Ingelheim Venture Fund★ Vivo Equity Investment Management
2021
Seed
Undisclosed
boehringer-ingelheim-venture.com
Offices
Shanghai, China · HQ / main office
Q&A
- What is RiboX Therapeutics' primary focus?
- RiboX Therapeutics is a global, clinical-stage biotechnology company focused on discovering and developing fully engineered circular RNA (circRNA) therapeutics to overcome limitations of mRNA therapeutics and realize the full potential of RNA medicines.
- When was RiboX Therapeutics founded?
- RiboX Therapeutics was founded in 2021.
- What is the total amount of funding RiboX Therapeutics has raised to date?
- RiboX Therapeutics has raised a total of $110,000,000 USD.
- Which investors participated in RiboX Therapeutics' latest funding round?
- In July 2022, RiboX Therapeutics completed a B Round with participation from Temasek.
- What therapeutic areas does RiboX Therapeutics' pipeline cover?
- RiboX Therapeutics' pipeline spans various therapeutic areas, including radiation-induced xerostomia, monogenic rare diseases, autoimmune diseases, and metabolic diseases.
- Where are RiboX Therapeutics' operations located?
- RiboX Therapeutics has operations in China, the US, and Israel.
- Who are the co-founders of RiboX Therapeutics?
- The co-founders of RiboX Therapeutics are Ling-Ling Chen, Dan Peer, and Weiyi Zhang.
- What is the current stage of RiboX Therapeutics?
- RiboX Therapeutics is currently in its Series B stage.
Team · 12
Weiyi Zhang
Founder · Chief Executive Officer
Jennifer Kang
Head of IP & Corporate Legal
Patrick Au
Head of Preclinical Development and Translational Medicine
Michelle Sun
Head of Clinical Development
Siqi Li
Head of Technology Platform
Mengyao Zheng
Head of CMC
Emma Pan
Head of Research
Roi Mashiach
Head of Site (Israel)
Mengtao Xiao
Head of Business Development
Mike Miao
Head of Business Operations
Haifa Tyler
Head of Clinical Operations
Yizhen Xu
Chief Medical Officer
Sectors & technology
Primary sector
Drug Discovery
Technologies
Target customers
Business model
Biopharmaceutical
Tags
biotechnologydrug-deliveryin-vivonanotechnologyrna-therapeutics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | riboxtx.com |
|---|
Identifiers & details
| Legal name | RiboX Therapeutics Ltd. |
|---|---|
| Founded | 2021 |
Radar intelligence
Patents
| EPO | 8 |
|---|
Web history (Wayback)
| Domain | riboxtx.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516590643 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2022-03-31 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | אינשטיין 18 נס ציונה |